AstraZeneca (LSE:AZN) received EU approval for its cancer treatment Imfinzi, marking a significant product-related milestone.

AstraZeneca AZN is one of the leading drugmakers in the oncology space. Oncology sales (comprising around 41% of ...

Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the ...

The approval comes amid speculation that the big pharma company may switch its UK stock market listing to the US.

TMUS, AZN, and CMCSA each face market headwinds, but new analyst reports highlight strengths shaping their outlooks.

Despite a Q1 revenue miss due to currency headwinds, core EPS beat expectations for AstraZeneca. Read why AZN stock is a Buy.

AstraZeneca’s Imfinzi receives European approval to treat patients with resectable muscle-invasive bladder cancer: Cambridge, UK Saturday, July 5, 2025, 09:00 Hrs [IST] AstraZen ...

AstraZeneca’s Imfinzi (durvalumab) has been approved in the European Union (EU) for the treatment of adult patients with resectable muscle-invasive bladder cancer (MIBC) in combination with ...

British drugmaker AstraZeneca (LSE: AZN) has gained European approval for Imfinzi (durvalumab) in combination with ...

Drugmaker AstraZeneca said on Friday that its Imfinzi asset has been approved in the EU as the first and only perioperative immunotherapy for muscle-invasive bladder cancer.

OPEN The FTSE 100 was expected to open 19.9 points lower on Friday after wrapping up the previous session 0.55% higher at 8,823.20.

Cambridge: AstraZeneca has received approval for Imfinzi (durvalumab) in the European Union (EU) for the treatment of adult ...